Targovax to prioritize resources on unlocking the potential of its circRNA platform
· Targovax has an early-mover advantage in circRNA, a novel area of RNA therapeutics attracting substantial interest from pharma and investors internationally · Targovax remains confident in the significant potential of ONCOS-102, but due to the currently challenging market conditions phase 2 development will only proceed once a partnership or additional financing is secured · The externally funded collaborative clinical studies with enhanced mutant RAS vaccine TG01 will proceed as planned in the USA and Norway · The new focus will significantly reduce costs and enable acceleration